PRODUCT TESTING
QUALITY WORKFLOW
Identity review
Product records are assessed against the stated compound, format, and documented batch context before release.
Analytical testing
Testing documentation is reviewed with a focus on batch-specific quality information, not unqualified performance claims.
Batch traceability
Every shipment is connected to a clear record of product format and the batch information used for its quality review.
Documented release
Quality language stays purpose-specific, so available records communicate research suitability without overstating clinical application.
INDEPENDENT TESTING SUMMARY
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
12.44 mg
Single reported sample result.
REPORTED PURITY
99.818%
Purity reported for the submitted sample.
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 12.44 mg peptide content and 99.818% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Nominal label claim: 10 mg blend
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED CJC-1295
5.11 mg
CJC-1295 (mod GRF 1-29) result.
REPORTED IPAMORELIN
5.39 mg
Ipamorelin result for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
25 Jul 2025
TASK NUMBER
#72769
TESTING ORDERED
18 Jul 2025
ANALYSIS DATE
28 Jul 2025
REPORT MANUFACTURER FIELD
aura
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Component-quantity results for the specific sample submitted to the laboratory; no purity result is stated.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 5.11 mg CJC-1295 (mod GRF 1-29) and 5.39 mg Ipamorelin for the submitted sample. No purity result is stated in the supplied report.
Those findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Nominal label claim: 5 mg + 5 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED IPAMORELIN
4.63 mg
Ipamorelin result for the submitted sample.
REPORTED CJC-1295
6.09 mg
CJC-1295 (mod GRF 1-29) result.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
20 Feb 2026
TASK NUMBER
#108207
TESTING ORDERED
15 Feb 2026
ANALYSIS DATE
26 Feb 2026
REPORT MANUFACTURER FIELD
glow
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Component-quantity results for the specific sample submitted to the laboratory; no purity result is stated.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 4.63 mg Ipamorelin and 6.09 mg CJC-1295 (mod GRF 1-29) for the submitted sample. No purity result is stated in the supplied report.
Those findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
9.38 mg
Single reported sample result.
REPORTED PURITY
99.560%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
14 May 2025
TASK NUMBER
#65127
TESTING ORDERED
28 Apr 2025
ANALYSIS DATE
15 May 2025
REPORT MANUFACTURER FIELD
yammi
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 9.38 mg peptide content and 99.560% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Nominal label claim: 50 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
52.86 mg
Single reported sample result.
REPORTED PURITY
99.893%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
20 Feb 2026
TASK NUMBER
#108210
TESTING ORDERED
15 Feb 2026
ANALYSIS DATE
27 Feb 2026
REPORT MANUFACTURER FIELD
glow
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 52.86 mg peptide content and 99.893% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Nominal label claim: 100 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
119.63 mg / 118.72 mg
Two tested-vial results reported.
REPORTED PURITY
99.608% / 99.649%
Two purity results reported.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
18 Sep 2025
TASK NUMBER
#80244
TESTING ORDERED
16 Sep 2025
ANALYSIS DATE
23 Sep 2025
REPORT MANUFACTURER FIELD
aura
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 119.63 mg / 118.72 mg peptide content and 99.608% / 99.649% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Ipamorelin | Batch C204
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
9.71 mg
Single reported simple result.
REPORTED PURITY
99.770%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
30 Jun 2026
TASK NUMBER
#200111
TESTING ORDERED
25 Jun 2026
ANALYSIS DATE
09 Jul 2026
REPORT MANUFACTURER FIELD
glow
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 9.71 mg peptide content and 99.770% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Kisspeptin | Batch C200
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
12.14 mg
Single reported simple result.
REPORTED PURITY
99.172%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
29 May 2026
TASK NUMBER
#167698
TESTING ORDERED
26 May 2026
ANALYSIS DATE
04 Jun 2026
REPORT MANUFACTURER FIELD
glow
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 12.14 mg peptide content and 99.172% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
KPV | Batch C117
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
12.45 mg
Single reported simple result.
REPORTED PURITY
99.487%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
20 Feb 2026
TASK NUMBER
#108214
TESTING ORDERED
15 Feb 2026
ANALYSIS DATE
26 Feb 2026
REPORT MANUFACTURER FIELD
glow
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 12.45 mg peptide content and 99.487% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
MOTS-C | Batch C117
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
11.26 mg
Single reported simple result.
REPORTED PURITY
99.047%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
20 Feb 2026
TASK NUMBER
#108218
TESTING ORDERED
15 Feb 2026
ANALYSIS DATE
28 Feb 2026
REPORT MANUFACTURER FIELD
glow
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 11.26 mg peptide content and 99.047% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
MOTS-C | Batch MS10/2025-05
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
10.35 mg
Single reported simple result.
REPORTED PURITY
99.753%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
14 May 2025
TASK NUMBER
#65126
TESTING ORDERED
28 April 2025
ANALYSIS DATE
15 Feb 2025
REPORT MANUFACTURER FIELD
yamni
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 10.35 mg peptide content and 99.753% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
PT-141 | Batch 546-890
Nominal label claim: Not Stated
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
10.41 mg
Single reported simple result.
REPORTED PURITY
99.760%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
07 May 2026
TASK NUMBER
#148535
TESTING ORDERED
16 April 2025
ANALYSIS DATE
12 May 2026
REPORT MANUFACTURER FIELD
yamni
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 10.41 mg peptide content and 99.760% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Retatrutide | Batch 86/800
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
10.42 mg
Single reported simple result.
REPORTED PURITY
99.794%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
29 Jan 2026
TASK NUMBER
#103742
TESTING ORDERED
24 Jan 2026
ANALYSIS DATE
02 Feb 2026
REPORT MANUFACTURER FIELD
glow
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 10.42mg peptide content and 99.794% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Selank | Batch green
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
11.15 mg / 10.95 mg
Two tested-vial results reported.
REPORTED PURITY
99.678% / 99.675%
Two purity results reported.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
19 Dec 2025
TASK NUMBER
#95281
TESTING ORDERED
19 Dec 2025
ANALYSIS DATE
22 Dec 2025
REPORT MANUFACTURER FIELD
aura
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 11.15 mg / 10.95 mg peptide content and 99.678% / 99.675% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Semax | Batch 50-502
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
12.38 mg
Single reported simple result.
REPORTED PURITY
99.529%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
25 Jun 2025
TASK NUMBER
#69431
TESTING ORDERED
18 Jun 2025
ANALYSIS DATE
27 Jun 2025
REPORT MANUFACTURER FIELD
aura
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 12.38 mg peptide content and 99.529% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
TB-500 (TB4) | Batch LIYU20250901
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
10.93 mg
Single reported simple result.
REPORTED PURITY
99.039%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
12 Sep 2025
TASK NUMBER
#78710
TESTING ORDERED
02 Sep 2025
ANALYSIS DATE
18 Sep 2025
REPORT MANUFACTURER FIELD
liyu
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 10.93 mg peptide content and 99.039% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Thymosin Alpha-1 | Batch C119
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
9.37 mg
Single reported simple result.
REPORTED PURITY
99.084%
Purity reported for the submitted sample.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
18 May 2026
TASK NUMBER
#163458
TESTING ORDERED
13 May 2026
ANALYSIS DATE
25 May 2026
REPORT MANUFACTURER FIELD
glow
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 9.37 mg peptide content and 99.084% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
INDEPENDENT TESTING SUMMARY
Tirzepatide | Batch 1102
Nominal label claim: 10 mg
ANALYTICAL REPORT REVIEWED
Results below are transcribed from the supplied Janoshik Analytical report.
REPORTED PEPTIDE CONTENT
10.61 mg / 10.33 mg
Two tested-vial results reported.
REPORTED PURITY
99.563% / 99.760%
Two purity results reported.
LABORATORY
Janoshik Analytical
SAMPLE RECEIVED
24 Nov 2025
TASK NUMBER
#90579
TESTING ORDERED
21 Nov 2025
ANALYSIS DATE
25 Nov 2025
REPORT MANUFACTURER FIELD
aura
Declared supply route: Advanced Peptides NL
WHAT THIS REPORT SUPPORTS
Content and purity results for the specific sample submitted to the laboratory.
BATCH VALIDITY: MAXIMUM 24 MONTHS
This maximum period does not replace applicable storage, stability, handling, or earlier-expiry requirements.
HOW TO INTERPRET THIS TESTING SUMMARY
The supplied Janoshik report records 10.61 mg / 10.33 mg peptide content and 99.563% / 99.760% purity for the submitted sample.
These findings are an analytical checkpoint for the tested material. They do not automatically extend to every vial carrying the same batch number, particularly where sampling, custody, repackaging, or distribution links have not been independently documented.
WHERE PATIENT BLOOD TESTS FIT
Relevant blood tests may help a qualified clinician monitor an individual patient response or identify risks. They cannot authenticate a vial, prove sterility, establish batch-wide quality, or by themselves demonstrate that a peptide is safe and effective.
BATCH NUMBER ON A VIAL IS NOT PROOF OF SAFETY
Labels and batch numbers can be copied, altered, or counterfeited. A matching number does not prove that a vial came from the stated manufacturer, remained within a secure supply chain, or contains material that is sterile, non-toxic, clinically safe, or effective.
JANOSHIK SOURCE-REPORT AND VERIFICATION INFORMATION
The analytical results summary were transcribed from an original Janoshik Analytical report supplied for review. The original submitting party retains the complete report and unique verification key; these are not published here. This customer-facing summary is not the original Janoshik certificate. Independent online verification requires both the task number and unique key and applies only to the submitted sample.
Testing information supports professional research evaluation only. It does not constitute a medical claim or a guarantee of therapeutic use.